In 2012, the USPSTF recommend against routine PSA screening. The aim of this study was to examine the implications of this recommendation for general and high-risk populations (i.e. patients with a family history of prostate cancer (PCa) as well as African-Americans). We developed a Monte Carlo simulation modeling the clinical progression of PCa with one arm undergoing PSA screens every 4 years and the other with patients not undergoing screening. Outcomes included quality-adjusted life years (QALYs) and PCa-related costs adjusted for QALYs. Our model found no survival benefit to routine PSA screening of the general population. However, African-American and family history patients in the screening arm had average survivals that were 0.47 and 0.57 QALYs higher than those not undergoing screening, respectively. PCa-related costs were nearly 2 and 2.5 times higher in the non-screening arm for the general population and both high-risk populations, respectively. These findings suggest that lack of routine screening may result in higher PCa-related costs and poorer survival outcomes for high-risk populations.
Introduction
Prostate cancer (PCa) is one of the most prevalent diseases today, representing the third most common cancer and the fifth leading cause of cancer death in the United States. The number of new cases in 2015 was estimated to be 220,800, representing 13 .3% of all new cancer diagnoses [1] . This represents enormous costs to the US healthcare system; the total cost of PCa-related care in 2010 was estimated to be roughly $12 billion [2] . As the segment of the aging population grows (projected to increase by 53.2% by 2020 by US Census estimates), the importance of finding optimal and cost efficient treatment strategies is paramount as the absolute prevalence of PCa will no doubt continue to rise [3] .
In the 1980s, prostate-specific antigen (PSA) began to be used as a means for the screening of PCa. Its use in clinical practice had immediate effects as the percentage of Stage 4 metastatic PCa at diagnosis dropped precipitously from roughly 25% in 1980 to 4% by 2002 [4] . However, in 2012, the US Preventive Services Task Force (USPSTF) in conjunction with the American Academy of Family Physicians (AAFP) recommended against the use of PSA in the diagnosis of PCa for the general population [5] . Shortly following this, the American Urological Association (AUA) also changed its stance, recommending against routine PSA screening and encouraging discussion of the test with men at higher risk [6] . Citing findings from the Prostate, Lung, and Colorectal, and Ovarian (PLCO) trial and European Randomized Study of Screening for Prostate Cancer (ERSPC), the USPSTF stated that the potential harms of PSA screening outweighed the benefits in question.
The PLCO found no significant difference in the relative risk (RR) of PCa-specific mortality between screening and non-screening arms (RR = 1.14; 95% CI: 0.76 -1.70) following annual PSA screening for 6 years [7] . However, the PLCO trial has been met with some skepticism as patients constituting the control arm of the trial likely were undergoing PSA screening prior to randomization to the non-screening arm (estimated to be 77%), which could underestimate the potential diagnostic advantage and mortality benefit of PSA screening [8] .
Unlike the PLCO, the ERSPC did find that PSA screening is associated with a small decline in all-cause mortality in patients aged 50-74 (0.11 fewer deaths per 1,000 people) with an RR of PCa specific-mortality of 0.73 (95% CI: 0.61-0.88) in the screening arm [9] . Using ERSPC data, simulations have found that PSA screening may be responsible for anywhere from 45-70% of the decline in PCa-specific mortality [10] . However, no study thus far has demonstrated a significant survival benefit with regard to all-cause mortality following PSA screening of all men over 50 years [5] .
Given the incongruent findings of multiple studies and simulations utilizing similar datasets, we set out to examine the implications of changes in PSA screening guidelines for PCa-related costs and quality-adjusted life years (QALYs).
Methods

Decision model
In our model, we simulate American men aged 50-69 taking one of two paths: either undergoing regular PSA screenings (i.e. every 4 years per Schröder et al.) or no PSA screens to evaluate the benefit of PSA screening for PCa-related mortality, utility, and cost [9] . We also proceed to use this model to determine whether PSA screening may be of greater utility for at-risk populations (i.e. patients with a family history of PCa as well as African-American men). A PSA cutoff of 4.0 ng/mL or greater constituted a positive PSA screen in our model. We defined the following three endpoints within our model: the patient not being diagnosed with PCa, the patient being diagnosed with Stage 1 PCa followed by treatment with radical prostatectomy (RP), or the patient being diagnosed and treated for Stage 4 metastatic PCa. We defined QALYs as well as cost per QALYs as the primary outcomes of our analysis.
Our decision tree can be found in Figure 1 . Microsimulations were run utilizing TreeAge Pro software (TreeAge Software Inc., Williamstown, MA). Patient survival, utility, and costs are described in the following paragraphs and were sampled from distributions once per trial with each simulation having 1000 individuals per arm. Trials were run multiple times to ensure similar means and distributions. Relevant probabilities and model inputs can be found in Table 1 , with relevant sections outlined below.
Chance Nodes
Given that one of the primary criticisms of PSA screening is the possibility of false positives, we included in our model not only the likelihood of patients going on to obtain a biopsy following a PSA screen but also the likelihood of the biopsy being positive. We used a weighted probability (given that patients with PSA between 4.0 ng/mL and 9.9 ng/mL are less than half as likely to be diagnosed with PCa as those with a PSA > 10.0 ng/mL) using population estimates from Schröder et al [11] . Also, given the possibility that patients in the non-screening arm of the PCLO trial might have undergone PSA screens in the past, we elected to use results from the ERSPC regarding the incidence of metastatic cancer in screening and nonscreening arms. Confidence intervals were included to account for variation in estimates at relevant chance nodes whenever listed in studies or could be calculated from sample sizes provided. We were unable to find studies examining the incidence of metastatic PCa for patients electing against biopsy following a positive PSA screening, so we utilized the incidence rate of metastatic cancer that was found in nonscreening arms for this sub-population of patients. We also assumed that patients who elected against prostate biopsy following a positive PSA screening would have the same likelihood of a positive biopsy than those who elected to have a biopsy performed.
Economic assumptions
Assumptions for lifetime PCa-related treatment costs conditional on staging were based on the estimates of Stokes et al. [12] . Patients not diagnosed with PCa in our model were assigned a PCa-related cost equal to that of undergoing 5 PSA screens (20 years with 4-year screening interval). If the PSA value was found to be positive (but did not eventually result in a diagnosis of cancer), then we also included costs relating to diagnostic studies and follow-up (i.e. the cost of the biopsy, pathology without clinical staging, and urology/medical oncology consultation). We assume that patients undergo some type of treatment following a diagnosis of PCa following biopsy as 90% of patients do elect to move forward with treatment [13] .
Utilities/QALYs
Patient preferences for health states are necessary to perform cost-utility studies. As such, we proceeded to use QALYs rather than overall survival to define outcomes associated with one of the three terminal states in our model. We also calculated the cost/QALY associated with one of the three outcomes defined in our model. This is necessary given that metastatic PCa has a much lower total treatment-related cost than that of lower stages, but this does not accurately reflect the much higher intensity of resource utilization in metastatic PCa cases as opposed to lower stage cases. We utilized data from Hayes et al. that has survival estimates associated with specific procedures and relevant outcomes (i.e. urinary incontinence or erectile dysfunction from RP) to discount the survival based on utility estimates relative to no PCa or metastatic cancer [14] . We derived the QALY estimate for metastatic cancer by using the utility estimate (0.12; 95% CI: 0.06 -0.24) for metastatic cancer established by Hayes et al. and multiplying this by the median survival of 3.7 years based on SEER data (demonstrated as a legitimate method of calculating QALYs) [15] . Notably, one assumption we make is that patients in the screening arm that undergo biopsy are diagnosed with PCa have no decline in QALY (as Hayes et al. did not look at this population to compare utility among those diagnosed and treated for PCa).
High-Risk Populations
We were also interested in evaluating whether screening may have a benefit for populations at higher risk of developing PCa, notably those with a family history of PCa as well as African-Americans. As such, we also ran Monte Carlo simulations for these two sub-populations using established odds ratios defined in the literature regarding increased likelihood of positive PSA screens as well as being diagnosed with PCa. The relevant odds ratios for both populations are presented in Table 2 . PCa patients with a family history have been demonstrated to have similar rates of metastatic cancer than those without a family history, so the same probabilities used for the general population were used for those with family history regarding limited or metastatic cancer incidence in screening and non-screening arms [16] . Similarly, epidemiological studies examining PCa among white and African-American veterans have found no statistically significance differences with regard to undergoing biopsy following a positive PSA, likelihood of positive biopsy following a positive PSA, or incidence of metastatic disease [17, 18] . 
Results
The expected total QALYs and cost/QALY for both screening and non-screening arms for all three populations examined are listed in Table 3 . Patients undergoing PSA screening every 4 years had 0.08 higher QALYs on average than those not undergoing regular screening (14.88 vs. 14.80). This result was not found to be statistically significant (p = 0.4396 following two sample t-test). However, PCa-related cost/QALY was found to be nearly two times as high in the non-screening arm ($2010.66) as compared to the screening arm ($1016.99; p = 0.0043 following two sample t-test).
We then proceeded to calculate the QALYs and PCa-related cost/QALY for both screening and nonscreening arms in patients with a family history of PCa. For those with a family history, we did find a statistically significant survival benefit of roughly 0. 
*Significant findings
Discussion
Microsimulations can be of great utility in addressing questions that have not been examined in the realworld setting. Notably, there have been a dearth of studies examining the possible benefit of PSA screening for patients at higher risk of developing PCa, such as African-Americans as well as those with a family-history of PCa. As such, this study aimed to utilize previous findings from multiple studies to compare mortality and cost outcomes between populations undergoing routine PSA screening as compared to those who did not. This is especially relevant given that following the USPSTF's recommendations, a statistically significant decline in the proportion of men aged 50-74 undergoing PSA screening has already been noted [31] .
Following a Monte Carlo simulation for the general population of men aged 50-69, we find that men undergoing screening had a similar average QALY as compared to those that did not undergo screening (14.88 and 14.80, respectively). Similar to our simulation findings, clinical trials by Andriole et al. demonstrated that cumulative PCa-related mortality in screening and non-screening arms that were not statistically significantly different (RR = 1.09, 95% CI = 0.87 to 1.36) [7] . Similarly, though many studies from the ERSPC have found significant reductions in PCa-specific mortality from screening, no significant benefit in all-cause mortality has been demonstrated [9, 20, 21] .
For African-Americans and those with a family history, the USPSTF had no recommendation for or against PSA screening given a paucity of data. Notably, in the PLCO trial, only 4% of enrolled men were non-Hispanic black, and the ERSPC is assumed to have a predominantly white cohort (racial demographics have not been provided/studied) [7] . The findings from our model suggest that patients with a family history or of African-American descent may benefit from screening. Patients with a family history and African-Americans were found to have statistically significantly survival benefits of 0.57 and 0.47 QALYs, respectively, suggesting that routine screening of such populations may still be indicated. This is quite dependent on the findings of Schröder et al., which demonstrated a likelihood of metastatic PCA approximately twice as high among patients with no PSA screens compared with those undergoing regular PSA screens every 4 years [21] . Notably, substantially lower rates of metastatic cancer in screening arms have been verified following correction for noncompliance and contamination in previous randomized clinical trials [32] .
With regard to PCa-related costs adjusted for quality-of-life and intensity of resource utilization (i.e. cost/QALY), we do find that a recommendation against screening of the general population has large implications. Based on our literature review and assuming current practice patterns, the outcome of Stage 4 metastatic PCa was assigned a mean cost/QALY of $62,449.06 as compared to $3,830.11 for Stage 1 PCa assuming a quality-of-life consistent with being treated with RP. As such, drastically higher incidences of metastatic cancer in non-screening compared to screening arms account for the higher cost/QALY demonstrated for all 3 populations examined. For the general population, this translated to a roughly two times greater cost/QALY in the non-screening arm, with such results being much more pronounced for African-American and family-history patients (roughly 2.5 as high in both populations). However, it is worth mentioning that the cost cited is an average of all Stage 1 cancers treated (i.e. encompasses different treatment modalities utilized). Cost estimates regarding lower stage PCa could change if active surveillance/watchful waiting was more commonplace for management of Stage 1 cases. This topic is one that is becoming an active area of research (i.e. the ProtecT trial in the UK is currently comparing active surveillance, radiotherapy, and RP) that may have large implications for management of early diagnosed cases of PCa and PCa-related costs in the US [33] .
One major limitation of our study is not accounting for possible declines in utility and subsequent QALYs associated with patients undergoing PSA screening and biopsy without a diagnosis of PCa, which favors the PSA screening arm. Similarly, we do not account for the possibility of lead-time bias in the PSA screening arm, which questions whether the all-cause mortality benefits demonstrated for higher-risk populations could still be demonstrated after adjusting for this. We also do not examine whether different screening intervals (i.e. annual screening versus screening every other year) may result in different outcomes. Also, we do not include outcomes for Stage 2 and 3 PCa. However, given that both total and PCa cancer-related costs between Stage 1 and Stages 2-3 are similar, we do not believe this would have drastically changed the results [12] . Similarly, while we utilize RP for the QALY estimates for Stage 1 cases and do not look at other modalities (i.e. active surveillance, radiotherapy, etc.), it is worth noting that QALY estimates from all of these treatment modalities had similar means and distributions and also likely would not have resulted in drastically different results [14] .
Conclusion
Our results suggest that there may be a survival benefit from screening for both African-Americans and those with a family-history of PCa. With regard to cost, we find that lack of screening of all 3 populations studied could lead to a much greater degree of resource utilization. Given initial findings from our model, randomized clinical trials examining the benefits of PSA screening for those with a family history of PCa and African Americans are warranted. Future studies aim at incorporating a Markov process into our model to better capitulate the complexity of PCa management as well as examining the impacts of screening for West Virginian populations.
